Browse the evidence

The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class, with gastrointestinal events being the most common adverse effects.

Practitioners should be aware of the gastrointestinal side effects associated with orforglipron, particularly during dose escalation.

The combination of Semaglutide and VLCD provoked greater improvements in pancreatic beta-cell function than VLCD alone.

Combining Semaglutide with VLCD may enhance pancreatic function in T2D management.

Higher dose levels of GLP-1RAs may have better effects on weight loss.

Consideration of dose levels may optimize weight loss outcomes with GLP-1RAs.

Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with bariatric metabolic surgery (BMS) (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).

Tirzepatide may be a safer option for reducing mortality in obese patients compared to surgical interventions.

Tirzepatide reduced the risk of major adverse cardiovascular events (MACEs) (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).

Tirzepatide may help reduce cardiovascular risks in obese patients.

Tirzepatide reduced the risk of major adverse kidney events (MAKEs) (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).

Tirzepatide may be beneficial for kidney health in obese patients.

Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.

Semaglutide may be an effective treatment option for improving liver histology in patients with MASH.

In the 15-mg tirzepatide group, 62% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 53 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

GLP-1 RA use is associated with increased risk of gallbladder or biliary diseases for longer durations (RR, 1.40; 95% CI, 1.26-1.56) compared to shorter durations (RR, 0.79; 95% CI, 0.48-1.31).

Clinicians should monitor patients on GLP-1 RAs for gallbladder issues, especially with prolonged use.

1-year reinitiation was lower for those without type 2 diabetes (36.3%) compared with those with type 2 diabetes (47.3%).

Practitioners should note that patients without type 2 diabetes may have lower rates of reinitiating GLP-1 RA therapy.

Weight loss achieved through GLP-1–based antiobesity medications affects weight regain, fat-free mass, and skeletal muscle mass in people with obesity.

Practitioners should consider the impact of GLP-1 medications on body composition when managing obesity.

Wegovy rose from 989 in 2021 to 2992 in 2022.

The increase in Wegovy usage suggests a rising interest in GLP-1 receptor agonists for weight loss.

The monthly growth rates were 83.9% for Ozempic and 119.2% for Wegovy.

High monthly growth rates indicate a significant trend towards the use of GLP-1 receptor agonists for weight loss.

Liraglutide, 3.0 mg, is safe with no serious adverse events or treatment-related deaths reported.

Liraglutide can be considered a safe option for weight management in the studied population.

Bariatric surgery and GLP-1 receptor agonists have similar effects on glycemic control.

Both treatment options can be considered for glycemic control in obese patients.

Tirzepatide treatment was associated with lower hazards of all-cause mortality compared to GLP-1 RA (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75).

Practitioners may consider tirzepatide as a safer option for reducing mortality risk in patients with type 2 diabetes.

Tirzepatide treatment was associated with lower hazards of major adverse cardiovascular events (MACEs) compared to GLP-1 RA (AHR, 0.80; 95% CI, 0.71-0.91).

Tirzepatide may be a preferable treatment option for reducing cardiovascular risks in patients with type 2 diabetes.

Twins on the vegan diet had a significant mean decrease in fasting insulin level of -2.9 μIU/mL after 8 weeks.

Clinicians may consider a vegan diet to improve insulin sensitivity in patients.

GLP-1 receptor agonists (semaglutide, liraglutide) significantly improve cardiovascular biomarkers—including hs-CRP, systolic blood pressure, and lipid profiles—independent of glycemic control.

GLP-1 medications like semaglutide do more than just help you lose weight; they directly improve your heart health markers. They significantly lower systemic inflammation (hs-CRP), improve blood vessel function, lower blood pressure, and improve lipid profiles. These benefits happen even if you don't have diabetes, proving the drug protects your blood vessels directly. You should be aware of the slightly increased risk of gallbladder issues due to rapid weight loss, so your doctor will monitor your baseline risk.

GLP1-RA treatment is associated with improvements in mental health-related quality of life compared with placebo (g = 0.15; P < .001).

GLP1-RAs may enhance mental health quality of life in this population.

There are quantitative sex differences in the response to GLP-1 and its analogs.

Practitioners should consider sex differences when prescribing GLP-1 analogs.

The share of prescriptions for semaglutide (Wegovy) increased to 27.7% among advanced practice practitioners (APPs) by February 2024.

Practitioners should consider the growing preference for semaglutide in obesity treatment.

The odds of discontinuation of glucose-lowering medications at year 1 differed by bMVPA timing, with the afternoon group having the highest odds (odds ratio 2.13).

Understanding the timing of physical activity may help in managing medication strategies for diabetes patients.

Tirzepatide resulted in significant decreases in systolic blood pressure of median -4.20 mmHg for 5 mg, -5.34 mmHg for 10 mg, and -5.77 mmHg for 15 mg.

Tirzepatide may be an effective treatment for reducing systolic blood pressure in patients.